Formally adding peptides to the FDA list of drugs safe for compounding requires federal rulemaking, a process involving public comments that can take years

Evolving US policy battles over drug pricing and healthcare affordability, tracking legislation, court rulings, regulatory actions, and industry responses shaping costs, access, and market dynamics.